Optimization of Microbiological Laboratory Detection Strategy for Patients in A Designated Hospital Treating Novel Coronavirus Pneumonia in Anhui Province

Author:

Chang Wenjiao,Shi Yuru,Qi Yingjie,Liu Jiaxing,Liu Ting,Chen Zhaowu,Zhang Wenjing,Wang Mengmeng,Liu Dongfeng,Yin Ming,Xu Jing,Yang Yun,Zhu Xiaowu,Ge Jing,Zhu Shu,Gao Yong,Ma Xiaoling

Abstract

AbstractNovel coronavirus pneumonia (NCP) is an emerging, highly contagious community acquired pneumonia (CAP) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Highly efficient and accurate microbiological laboratory assay is essential to confirm the SARS-CoV-2 infection, rule out other pathogens that can cause CAP, and monitor secondary infections. Here, we enrolled and provide microbiological analysis for 129 suspected and 52 transferred confirmed NCP patients hospitalized in the First Affiliated Hospital of University of Science and Technology of China (USTC) from Jan 21 to Feb 29, 2020. By analyzing the dual swab samples (sputum and pharyngeal) from 129 suspected patients with realtime RT-PCR, we confirmed 33 SARS-CoV-2 infections, with two co-infection cases with adenovirus or rhinovirus. We also used multiplex PCR to detect 13 common respiratory tract pathogens in 96 non-NCP patients, and found that 30 patients (31.25%) were infected with at least one respiratory tract pathogen that may cause CAP. Further, we performed bacterial and fungal cultures as well as fungal serologic tests and found that there is no secondary bacterial/fungal infections in confirmed NCP patients. Our studies suggest that, during the epidemic of NCP in Anhui province, there was a certain proportion of infection and co-infection of other common pathogens of CAP, and the secondary bacterial and fungal infection is not detectable in NCP patients. In comparison with SARS-CoV-2 detection alone, this optimized strategy combining multiple pathogen detection for identification of NCP and other CAP patients as well as cultures and serologic tests for confirmed patients increases the diagnosis efficiency and facilitates the personalized medication.

Publisher

Cold Spring Harbor Laboratory

Reference23 articles.

1. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

2. Y.M. Arabi , S. Murthy , S. Webb , COVID-19: a novel coronavirus and a novel challenge for critical care, Intensive Care Med (2020).

3. S. Bernard Stoecklin , P. Rolland , Y. Silue , A. Mailles , C. Campese , A. Simondon , M. Mechain , L. Meurice , M. Nguyen , C. Bassi , E. Yamani , S. Behillil , S. Ismael , D. Nguyen , D. Malvy , F.X. Lescure , S. Georges , C. Lazarus , A. Tabai , M. Stempfelet , V. Enouf , B. Coignard , D. Levy-Bruhl , T. Investigation , First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020, Euro Surveill 25(6) (2020).

4. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

5. A novel coronavirus outbreak of global health concern

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3